Phenotype of postural instability/gait difficulty in Parkinson disease: relevance to cognitive impairment and mechanism relating pathological proteins and neurotransmitters.
Parkinson disease (PD) is identified as tremor-dominant (TD) and postural instability and gait difficulty (PIGD) phenotypes. The relationships between motor phenotypes and cognitive impairment and the underlying mechanisms relating pathological proteins and neurotransmitters in cerebrospinal fluid (CSF) are unknown. We evaluated the motor symptoms and cognitive function by scales, and detected the levels of pathological proteins and neurotransmitters in CSF. TD group and PIGD group had significantly higher levels of total tau, tau phosphorylated at the position of threonine 181(P-tau181t), threonine 231, serine 396, serine 199 and lower β amyloid (Aβ)1-42level in CSF than those in control group; PIGD group had significantly higher P-tau181t level and lower Aβ1-42level than those in TD group. In PD group, PIGD severity was negatively correlated with MoCA score and Aβ1-42level in CSF, and positively correlated with Hoehn-Yahr stage and P-tau181t level in CSF. In PIGD group, PIGD severity was negatively correlated with homovanillic acid (HVA) level in CSF, and HVA level was positively correlated with Aβ1-42level in CSF. PIGD was significantly correlated with cognitive impairment, which underlying mechanism might be involved in Aβ1-42aggregation in brain and relevant neurochemical disturbance featured by the depletion of HVA in CSF.
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, China.
Li-Jun
LJ
Zuo
Department of Geriatrics, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, China.
Ying-Shan
YS
Piao
Department of Geriatrics, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, China.
Li-Xia
LX
Li
Department of Geriatrics, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, China.
Shu-Yang
SY
Yu
Department of Geriatrics, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, China.
Peng
P
Guo
Department of Geriatrics, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, China.
Yang
Y
Hu
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, China.
Teng-Hong
TH
Lian
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, China.
Rui-Dan
RD
Wang
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, China.
Qiu-Jin
QJ
Yu
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, China.
Zhao
Z
Jin
Core Laboratory for Clinical Medical Research, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, China.
Ya-Jie
YJ
Wang
Department of Neurobiology and Physiology, Capital Medical University, Beijing, 100069, China.|Key Laboratory for Neurodegenerative Disorders of the Ministry of Education, Capital Medical University, Beijing, 100069, China.|Beijing Institute for Brain Disorders, Capital Medical University, Beijing, 100069, China.|Beijing Key Laboratory on Parkinson disease, Beijing, 100053, China.
Xiao-Min
XM
Wang
Key Laboratory for Neurodegenerative Disorders of the Ministry of Education, Capital Medical University, Beijing, 100069, China.|Beijing Institute for Brain Disorders, Capital Medical University, Beijing, 100069, China.|Beijing Key Laboratory on Parkinson disease, Beijing, 100053, China.|Department of Neurobiology, Beijing Institute of Geriatrics, Xuanwu Hospital of Capital Medical University, Beijing, 100053, China.
Piu
P
Chan
Department of Neurology, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China.
Sheng-Di
SD
Chen
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, China.|China National Clinical Research Center for Neurological Diseases, Beijing, 100050, China.
Yong-Jun
YJ
Wang
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, China.|Department of Geriatrics, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100050, China.|Key Laboratory for Neurodegenerative Disorders of the Ministry of Education, Capital Medical University, Beijing, 100069, China.|Beijing Institute for Brain Disorders, Capital Medical University, Beijing, 100069, China.|Beijing Key Laboratory on Parkinson disease, Beijing, 100053, China.|China National Clinical Research Center for Neurological Diseases, Beijing, 100050, China.
Wei
W
Zhang
D000368:Aged; D016229:Amyloid beta-Peptides / Q000378:metabolism; D015415:Biomarkers; D016022:Case-Control Studies; D003071:Cognition; D060825:Cognitive Dysfunction / Q000175:diagnosis / Q000209:etiology; D005260:Female; D020233:Gait Disorders, Neurologic / Q000175:diagnosis* / Q000209:etiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009043:Motor Activity; D009483:Neuropsychological Tests; D018377:Neurotransmitter Agents / Q000378:metabolism; D010300:Parkinson Disease / Q000150:complications* / Q000175:diagnosis* / Q000378:metabolism; D010446:Peptide Fragments / Q000378:metabolism; D010641:Phenotype; D012678:Sensation Disorders / Q000175:diagnosis* / Q000209:etiology*; D012720:Severity of Illness Index; D016875:tau Proteins / Q000378:metabolism
D016229:Amyloid beta-Peptides; D015415:Biomarkers; D018377:Neurotransmitter Agents; D010446:Peptide Fragments; C075222:amyloid beta-protein (1-42); D016875:tau Proteins